
|Articles|July 15, 2004
Toric IOL outperforms comparable spherical lens in FDA trial
San Diego - The AcrySof Toric IOL (Alcon Laboratories, Fort Worth, TX) is outperforming a comparable spherical IOL in uncorrected visual acuity (UCVA) levels and the low level of residual astigmatism. The interim safety and efficacy results of the FDA clinical trial of the AcrySof Toric IOL were presented here at the annual meeting of the American Society of Cataract and Refractive Surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5



























